cagrilintide trial New in the August 14, 2025, issue of NEJM: Cagrilintide–Semaglutide for Overweight or Obesity (REDEFINE 1 phase 3a trial) https://nej.md/444aW7f Cagrilintide–Semaglutide for Overweight and Diabetes (REDEFINE 2 phase 3a trial) https://nej.md/4ehQwLk Weight Loss Efficacy of Cagrilintide

The preservative acts as a guardian against microbial growth, allowing consistent peptide access throughout extended studies

Wegovy tablets and injections are FDA-approved in adults for: weight loss and weight management in adults with obesity or adults who are overweight and have a weight-related medical problem (e.g., blood pressure, type 2 diabetes, or high cholesterol) reducing major cardiovascular event risks (such as heart attack, stroke, or death) in adults with established CV disease and either obesity or overweight Wegovy injection is also FDA-approved for: weight loss and weight management patients with obesity who are 12 years and older non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), this is an accelerated approval

Hidden dangers Even though the early results seem exciting, these experimental compounds can be dangerous

Current treatments are largely palliative and do not address the underlying fibrosis

In a randomized, double-blind trial where women applied GHK-Cu encapsulated in a nano-lipid carrier twice daily for 8 weeks, the treatment group saw significant improvements in wrinkle depth and volume with no serious adverse events